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The antifungal activity of tacrolimus in combination with antifungal agents against dif-
ferent fungal species has been previously reported. Here we report the in vitro interactions
between tacrolimus and amphotericin B, ﬂuconazole, itraconazole, and caspofungin against
30  clinical isolates of both ﬂuconazole-susceptible and ﬂuconazole-resistant Trichosporon
asahii.  For these analyses, we used the broth microdilution method based on the M27-
A3  technique and checkerboard microdilution method. Tacrolimus showed no activity
against T. asahii strains (minimal inhibitory concentrations, MICs > 64.0 g mL−1). However, a
larger synergistic interaction was observed by the combinations tacrolimus + amphotericin
B  (96.67%) and tacrolimus + caspofungin (73.33%) against ﬂuconazole-susceptible isolates.
Combinations with azole antifungal agents resulted in low rates of synergism for this group
(ﬂuconazole + tacrolimus = 40% and itraconazole + tacrolimus = 10%). Antagonistic interac-
tions  were not observed. For the ﬂuconazole-resistant T. asahii group, all tested combinations
showed indifferent interactions. The synergism showed against ﬂuconazole-susceptible T.
asahii  isolates suggests that the potential antifungal activity of tacrolimus deserves in vivo
experimental investigation, notably, the combination of tacrolimus with amphotericin B orcaspofungin.©  2016 Sociedade Brasil
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Introduction
The incidence of invasive mycoses caused by emergent fungal
pathogens has proportionally grown with the increased num-
ber of immunocompromised hosts, such as AIDS patients,
transplant recipients treated with immunosuppressive drugs,
and those on cancer therapy.1–3 Trichosporon asahii is the most
frequently involved species in disseminated and deep-seated
trichosporonosis including systemic infections due to thera-
peutic failure in transplanted patients.2,3
The ﬁrst-line treatment for trichosporonosis includes the
use of azole antifungal agents, since Trichosporon spp. is resis-
tant to amphotericin B and echinocandins.4–6 However, the
frequent exposure to azoles can lead to development of sec-
ondary resistance to azoles and sometimes to multidrug
resistance, resulting in therapeutic failures7–9 and increas-
ing mortality rates.1,10 Combination therapy is a rational
alternative that has been studied to improve the efﬁcacy of
antimicrobial therapy for difﬁcult-to-treat infections, includ-
ing overcoming concerns of antimicrobial resistance.11–13
Recent studies have shown that using fungal calcineurin
pathways holds great promise for the future development of
novel agents, including combination therapy with antifun-
gals against fungal pathogens.14–17 The antifungal activity
obtained by the combination of the calcineurin inhibitor
tacrolimus (FK506) plus antifungal agents has not yet been
evaluated against Trichosporon species. In this context, the
aim of this study was to evaluate the in vitro activity of the
combination of FK506 with amphotericin B, ﬂuconazole, itra-
conazole, and caspofungin against ﬂuconazole-susceptible
and ﬂuconazole-resistant T. asahii strains.
Material  and  methods
Clinical  isolates  and  molecular  identiﬁcation
One group of 30 ﬂuconazole-susceptible (FS) strains of clin-
ical isolates T. asahii maintained in the collection of the
Department of Microbiology and Parasitology at the Fed-
eral University of Santa Maria, Santa Maria, RS, Brazil were
studied. A second group of ﬂuconazole-resistant strains (FR)
(n = 30) was obtained from the FS group after sequential
exposure to growing concentrations of ﬂuconazole, as previ-
ously described by Fekete-Forgacs et al.,18 with the following
modiﬁcations: the ﬁnal concentration of ﬂuconazole was
128 g mL−1, and the incubation temperature was 35 ◦C with
shaking for 48 h. Cells from this culture were plated on SDA
plates, and a single colony was designated isolated FR. The
standard strain T. asahii CBS 2479 was also included in the
susceptibility tests.
The identity of these isolates was conﬁrmed using standard
microbiological and molecular methods. Total DNA was
extracted according to the protocol described by Moller et al.19
and Klassen et al.20 with modiﬁcations. Ampliﬁcation of the
IGS1 region (rDNA intergenic) was performed by PCR using
the primers 26F (5′ATCCTTTGCAGACGACTTGA-3′) and 5SR
(5′AGCTTGACTTCGCAGATCGG-3′).5 The PCR products were
puriﬁed and sequenced. These sequences have been deposited
in GenBank (http://www.ncbi.nlm.nih.gov/genbank/) with the 1 6;2  0(6):539–545
following accession numbers: KR233249, KT438844, KR872655,
KR872656, KR872657, KR872660, KR872661, KR233246,
KR233247, KR233248, KT365854, KT365855, KR872662,
KT438839, KT438840, KR872663, KR912056, KT438842,
KT365856, KT438847, KR912058, KR912064, KT365858,
KR912065, KT365859, KT438846, KT365860, KR912059,
KT365861, KR912066.
Chemicals
Amphotericin B (AMB) (Sigma Chemical Co. – St. Louis, MO,
USA), ﬂuconazole (FCZ) (Sigma Chemical Co. – St. Louis, MO,
USA), itraconazole (ITZ) (Frangon of Brazil, Pharmaceutical,
Ltd., São Paulo, Brazil), caspofungin (CAS) (Merck, Darmstadt,
Germany), and tacrolimus (FK506) (Janssen-Cilag Pharmaceu-
tica, Beerse, Belgium) were employed.
The stock solutions of the drugs were prepared in dimethyl
sulfoxide (DMSO, Sigma Chemical Co.), except for FCZ, which
was diluted in sterile distilled water. FK506 was dissolved in
methanol. Working solutions were prepared according to the
document M27-A3 of the Clinical and Laboratory Standards
Institute.21
In  vitro  susceptibility  and  drug  interaction  tests
Susceptibility assays were performed using the broth microdi-
lution method, as described by the document M27-A3 of the
Clinical and Laboratory Standards Institute.21 The strains Can-
dida krusei ATCC 6258 and Candida parapsilosis ATCC 22019 were
included in the tests as controls. The minimum inhibitory
concentrations (MICs) were deﬁned as the lowest drug con-
centration able to inhibit 50% (for FCZ, ITZ, and CAS) or 100%
(for AMB  and FK506) of fungal growth when compared to
the growth of the control. The highest concentrations used
were 16 g mL−1 for AMB, 128 g mL−1 for FCZ, 16 g mL−1 for
ITZ and 64 g mL−1 for CAS and FK506. The MICs employed
as indicators for resistance were: ≥2 g mL−1 (AMB)5,22,23;
≥64 g mL−1 (FCZ)6,24; ≥1 g mL−1 (ITZ),23 and ≥2 g mL−1
(CAS).5,23 After exposing the strains to growing concentra-
tions of FLZ, the strains were separated in two groups: (a) FS
group (ﬂuconazole-susceptible group), formed by the strains
not exposed to FLZ; and (b) FR group (ﬂuconazole-resistant
group) formed by the same strains after exposure to FLZ, and
now showing MICs ranging from 64 to 128 g mL−1.
In vitro combinations of antifungal agents with FK506
against the FS and FR groups of T. asahii were evaluated by the
microdilution checkerboard method.25 For the calculation of
the fractional inhibitory concentration index (FICI), MIC values
related to 100% inhibition of growth were used. Synergism was
deﬁned as the FICI ≤ 0.5, indifference was 0.5 < FICI ≤ 4.0, and
antagonism FICI > 4.0. The FICIs were calculated for all wells
along the turbidity/non-turbidity interface where the lowest
FICI as the ﬁnal point was determined.
Statistical  analysisThe statistical analysis used to test the Susceptibility of the
two groups (susceptible strains vs.  resistant strains) to treat-
ment with individual antifungal agents was analyzed with
the t-test. Statistical signiﬁcance was set at p < 0.05. Results
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ere analyzed using the software Graph Pad Prism5 (Graph
ad Software version 6.01, CA).
esults
he in vitro susceptibilities of 30 T. asahii isolates (FS) against
he antifungal agents and FK506 are described in Table 1. FS
trains showed low MICs range for FCZ (1.0–16.0 g mL−1) and
TZ (0.13–1.0 g mL−1) compared to FR strains: FCZ (64.0 to
128.0 g mL−1) and ITZ (0.5–16.0 g mL−1). Interestingly, for
MB,  the number of resistant isolates decreased (90–3.33%) in
he FR group (MIC range = 0.13–4.0 g mL−1); and for CAS the
ICs remained similar in the two groups (MIC range for FS or
R = 4.0–16.0 g mL−1). FK506 did not show antifungal activity
gainst FS and FR isolates at the highest concentration tested
MICs > 64.0 g mL−1). The statistical analysis showed signiﬁ-
ant differences between the susceptibility of FS vs. FR groups
or azole antifungal agents (FLZ: p < 0.0001, ITZ: p < 0.007), as
ell as for AMB  (p < 0.0001) and CAS (p < 0.0001).
The MICs and combinations results of antifungal agents
nd tacrolimus against T. asahii before and after resistance
nduction are presented in Tables 2 and 3. FK506 com-
ined with AMB  against the FS T. asahii isolates showed the
ighest percentage of synergism (96.67%), followed by the
ombination with CAS (73.33%). In the synergistic interac-
ions between AMB + FK506 or CAS + FK506, the MIC  values
f FK506 decreased from 64 g mL−1 to 0.5 g mL−1. In con-
rast, in the FR group the majority of combinations with FK506
howed interactions classiﬁed as indifferent: AMB (76.67%),
AS (73.33%), FCZ (63.33%) and ITZ (50%). Antagonisms were
ot detected for combinations with FCZ and CAS but were
howed with AMB  (13.33%) and ITZ (10%).
iscussion
. asahii is the most frequently involved species in dissemi-
ated fungal infections including cases of systemic infection
n transplanted patients related to therapeutic failures.2,3 The
rognosis of trichosporonosis is very poor, showing mortal-
ty rates as high as 80%.1,10 The lack of response to therapy is
elated to the relative resistance of T. asahii to many  different
ntifungals.3,4,7,9
Table 1 – In vitro susceptibility of Trichosporon asahii isolates to 
Agents Group of isolates Geometric mean MIC range 
AMB FS 2.24 1.0–8.0 
FR 0.41 0.13–4.0 
FCZ FS 2.41 1.0–16.0 
FR 64.00 64.0 to >128.0 
ITZ FS 0.27 0.13–1.0 
FR 1.52 0.5–16.0 
CAS FS 7.82 4.0–16.0 
FR 7.29 4.0–16.0 
FK506 FS ND >64.0 
FR ND >64.0 
MIC range, minimal inhibitory concentration range (g mL−1); MIC50, MIC
90% of isolates tested were inhibited; AMB, amphotericin B; FCZ, ﬂuconaz
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Moreover, the correct identiﬁcation of Trichosporon species
is important because the susceptibility is species dependent.
In agreement with previous reports,10,26,27 our results conﬁrm
that T. asahii clinical isolates seem to be more  resistant in vitro
to amphotericin B than to triazole compounds (Table 1).
Interestingly, our ﬁndings demonstrated that after sequen-
tial exposure to growing concentrations of ﬂuconazole, the
number of resistant isolates to AMB  (MIC values ≥2 g mL−1)
decreased from 90% to 3.33% (Table 1). Although this inverse
relationship has been previously reported,5,7,27,28 targeted
deletion of ERG3 or ERG11 in Candida albicans and Candida
glabrata seems to be a potential mechanism that may lead to
increased susceptibility to AMB with increased resistance to
azoles.29,30
Similarly, clinical failure and breakthrough infections
with Trichosoporon have been reported with the use of
echinocandins.3,31–34 As expected, we found MICs ≥ 4 g mL−1
for caspofungin in all our isolates (Table 1). The cases
of intrinsic resistance to echinocandins already described
for Cryptococcus spp., Trichosporon spp., Fusarium spp., and
zygomycetes are associated with insufﬁcient sensitivity of the
target enzyme, beta 1,3-d-glucan synthase, to the drug or a
mutated form of the enzyme that precludes echinocandin
binding.35
Regarding the azole antifungal agents, our results demon-
strated that prolonged exposure of the clinical isolates to
ﬂuconazole showed an increased MIC for itraconazole char-
acterizing cross-resistance among azoles (Table 1). Multidrug
resistance to antifungal agents has been reported for T.
asahii in previous studies.4,7,9 T. asahii clinical isolates from
nongranulocytopenic patients showed reduced susceptibil-
ity in vitro to AMB, ﬂucytosine, ﬂuconazole, itraconazole and
ketoconazole.7 Kushima et al.9 described that long term use
of ﬂuconazole in vivo may lead to replacement of the amino
acid ERG11p and thus trigger T. asahii resistance to multiple
drugs. This study demonstrated that the MICs for other azole
antifungal agents against T. asahii strains increased in paral-
lel with the MIC for ﬂuconazole, while the AMB  MICs did not
signiﬁcantly change.9Tacrolimus (previously known as FK506) is an effective
immunosuppressant, obtained from Streptomyces tsukubaensis,
and is widely used for prevention of transplant rejection.36
antifungal agents and tacrolimus.
MIC50 MIC90 Number (%) of resistant isolates
2.0 4.0 27 (90)
0.25 1.0 1 (3.33)
2.0 8.0 0 (0)
64.0 64.0 30 (100)
0.25 0.50 1 (3.33)
1.0 4.0 27 (90)
8.0 8.0 30 (100)
8.0 8.0 30 (100)
ND ND ND
ND ND ND
 at which 50% of isolates tested were inhibited; MIC90, MIC at which
ole; ITZ, itraconazole; CAS, caspofungin; FK506, tacrolimus; FS e FR,
es; ND, not determined.
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Table 2 – Minimal inhibitory concentrations (MICs) and combinations results of antifungal agents and tacrolimus against
Trichosporon asahii before resistance induction.
Isolates  MICs  (g  mL−1)  and  combinations  results  before  resistance  induction
AMB/FK506  FCZ/FK506  ITZ/FK506  CAS/FK506
On  its  own  In  the
combination
On  its  own  In  the
combination
On  its  own  In  the
combination
On  its  own  In  the
combination
06  2.00  0.50  S  8.00  1.00  I 1.00  2.00  I 32.00  8.00  S
>64.00 0.50  >64.00  32.00  >64.00  0.50  >64.00  0.50
11 2.00 0.25 S  2.00  1.00  I 1.00  2.00  I 16.00  8.00  I
>64.00 0.50  >64.00  8.00  >64.00  0.50  >64.00  0.50
13 2.00  0.50  S  4.00  1.00  S  1.00  1.00  I 16.00  8.00  I
>64.00 0.50 >64.00 4.00 >64.00 0.50 >64.00 0.50
19 2.00  0.25  S  4.00  1.00  S  1.00  1.00  I 32.00  8.00  S
>64.00 0.50  >64.00  16.00  >64.00  0.50  >64.00  0.50
21 2.00  0.50  S  32.00  1.00  I 2.00  2.00  I 32.00  8.00  S
>64.00 0.50  >64.00  64.00  >64.00  0.50  >64.00  0.50
29 4.00  1.00  S  64.00  1.00  I 2.00  2.00  I 32.00  8.00  S
>64.00 0.50 >64.00 64.00  >64.00  0.50  >64.00  0.50
31 2.00  0.25  S  4.00  1.00  S  1.00  1.00  I 32.00  8.00  S
>64.00 0.50  >64.00  16.00  >64.00  0.5  >64.00  0.50
32 4.00  1.00  S  16.00  1.00  I 2.00  1.00  I 32.00  16.00  I
>64.00 0.50  >64.00  64.00  >64.00  0.50  >64.00  0.50
36 1.00  0.13  S  8.00  1.00  I 1.00  1.00  I 32.00  8.00  S
>64.00 0.50 >64.00 32.00  >64.00  0.50  >64.00  0.50
43 2.00  0.25  S  64.00  1.00  S  1.00  0.25  S  32.00  4.00  S
>64.00 0.50  >64.00  4.00  >64.00  0.50  >64.00  0.50
44 4.00  0.25  S  8.00  1.00  I 1.00  2.00  I 32.00  16.00  I
>64.00 0.50  >64.00  32.00  >64.00  0.50  >64.00  0.50
46 2.00 0.50 S  4.00  1.00  I 1.00  1.00  I 32.00  16.00  I
.>64.00 0.50  >64.00  32.00  >64.00  0.50  >64.00  0.50
47 8.00  0.50  S  32.00  1.00  I 2.00  1.00  I 64.00  8.00  S
>64.00 0.50  >64.00  32.00  >64.00  0.50  >64.00  0.50
48 2.00  0.50  S  8.00  1.00  I 1.00  1.00  I 32.00  8.00  S
>64.00 0.50 >64.00  32.00  >64.00  0.50  >64.00  0.50
49 2.00  0.25  S  16.00  1.00  S  1.00  1.00  I 32.00  8.00  S
>64.00 0.50  >64.00  16.00  >64.00  0.50  >64.00  0.50
50 2.00  0.25  S  8.00  1.00  S  1.00  1.00  I 32.00  16.00  I
>64.00 0.50  >64.00  16.00  >64.00  0.50  >64.00  0.50
51 4.00  0.25  S  2.00  1.00  I 1.00  1.00  I 32.00  16.00  I
>64.00 0.50 >64.00 8.00  >64.00  0.50  >64.00  0.50
53 4.00  0.25  S  4.00  1.00  S  2.00  0.50  S  16.00  16.00  I
>64.00 0.50  >64.00  16.00  >64.00  0.50  >64.00  0.50
54 2.00  0.50  S  8.00  1.00  I 1.00  1.00  I 32.00  8.00  S
>64.00 0.50  >64.00  32.00  >64.00  0.50  >64.00  0.50
56 2.00  0.50  S  8.00  1.00  I 1.00  0.50  I 32.00  8.00  S
>64.00 0.50  >64.00  32.00  >64.00  0.50  >64.00  0.50
58 2.00  0.50  S  16.00  1.00  I 1.00  1.00  I 32.00  8.00  S
>64.00 0.50  >64.00  32.00  >64.00  0.50  >64.00  0.50
59 1.00  0.50  I  16.00  1.00  S  1.00  0.25  S  64.00  8.00  S
>64.00 0.50  >64.00  8.00  >64.00  0.50  >64.00  0.50
60 2.00  0.25  S  8.00  1.00  S  1.00  2.00  I 32.00  8.00  S
>64.00 0.50  >64.00  16.00  >64.00  0.50  >64.00  0.50
61 8.00  0.50  S  8.00  1.00  I 1.00  2.00  I 32.00  8.00  S
>64.00 0.50  >64.00  32.00  >64.00  0.50  >64.00  0.50
62 2.00  0.25  S  8.00  1.00  I 1.00  2.00  I 32.00  8.00  S
>64.00 0.50  >64.00  32.00  >64.00  0.50  >64.00  0.50
63 2.00  0.50  S  8.00  1.00  S  1.00  0.02  I 32.00  8.00  S
>64.00 0.50  >64.00  16.00  >64.00  64.00  >64.00  0.50
64 2.00  0.25  S  4.00  1.00  S  0.50  2.00  I 32.00  8.00  S
>64.00 0.50  >64.00  8.00  >64.00  0.50  >64.00  0.50
65 4.00  0.25  S  8.00  1.00  I 0.50  2.00  I 32.00  8.00  S
>64.00 0.50  >64.00  32.00  >64.00  0.50  >64.00  0.50
66 2.00  0.50  S  8.00  1.00  I 1.00  2.00  I 32.00  8.00  S
>64.00 0.50  >64.00  64.00  >64.00  0.50  >64.00  0.50
67 1.00  0.25  S  4.00  1.00  S  1.00  2.00  I 32.00  8.00  S
>64.00 0.50  >64.00  16.00  >64.00  0.50  >64.00  0.50
MICs,  minimal  inhibitory  concentrations  as  the  lowest  concentration  that  showed  100%  inhibition  of  fungal  growth  (g  mL−1);  AMB,
amphotericin B;  FCZ,  ﬂuconazole;  ITZ,  itraconazole;  CAS,  caspofungin;  FK506,  tacrolimus;  S,  synergism;  I,  indifference.
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Table 3 – Minimal inhibitory concentrations (MICs) and combinations results of antifungal agents and tacrolimus against
Trichosporon asahii after resistance induction.
Isolates  MICs  (g  mL−1)  and  combinations  results  after  resistance  induction
AMB/FK506  FCZ/FK506  ITZ/FK506  CAS/FK506
On  its  own  In  the
combination
On  its  own  In  the
combination
On  its  own  In  the
combination
On  its  own  In  the
combination
06  1.00  0.50  I  >128.00  32.00  S  >16.00  2.00  S  16.00  8.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
11 0.25 0.25 I  128.00  32.00  S  4.00  1.00  S  8.00  4.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
13 0.50  0.50  I  >128.00  64.00  I >16.00  4.00  S  16.00  8.00  I
>64.00 0.50 >64.00 0.50 >64.00 0.50 >64.00 0.50
19 0.50  0.25  I  128.00  64.00  I 4.00  2.00  I 16.00  8.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
21 0.25  0.25  I  128.00  32.00  S  2.00  1.00  I 32.00  8.00  S
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
29 1.00  0.25  S  128.00  128.00  I >16.00  8.00  I 16.00  32.00  I
>64.00 0.50 >64.00 0.50  >64.00  0.50  >64.00  0.50
31 0.50  0.13  S  128.00  128.00  I 4.00  0.50  S  16.00  8.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
32 0.25  0.50  I  128.00  128.00  I >16.00  4.00  S  16.00  32.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
36 0.50  0.25  I  128.00  64.00  I 2.00  2.00  I 16.00  4.00  S
>64.00 0.50 >64.00 0.50  >64.00  0.50  >64.00  0.50
43 0.25  0.25  I  128.00  32.00  S  2.00  1.00  I 16.00  4.00  S
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
44 0.25  0.25  I  128.00  32.00  S  >16.00  2.00  S  16.00  8.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
46 1.00 1.00 I  128.00  128.00  I >16.00  2.00  S  16.00  16.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
47 4.00  0.25  S  64.00  64.00  I 2.00  2.00  I 16.00  16.00  I
>64.00 5.00  >64.00  0.50  >64.00  0.50  >64.00  0.50
48 0.50  0.25  I  >128.00  32.00  S  4.00  1.00  S  16.00  4.00  S
>64.00 0.50 >64.00  0.50  >64.00  0.50  >64.00  0.50
49 0.50  0.25  I  128.00  64.00  I 8.00  2.00  S  16.00  8.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
50 0.50  0.25  I  128.00  32.00  S  >16.00  1.00  S  16.00  8.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
51 0.25  0.25  I  128.00  32.00  S  2.00  2.00  I 16.00  8.00  I
>64.00 0.50 >64.00 0.50  >64.00  0.50  >64.00  0.50
53 0.25  0.50  I  128.00  128.00  I 2.00  16.00  A  16.00  8.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
54 0.25  0.13  I  128.00  64.00  I >16.00  1.00  I 16.00  16.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
56 0.13  0.50  A  >128.00  64.00  I >16.00  8.00  I 16.00  8.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
58 0.50  2.00  A  128.00  128.00  I 8.00  32.00  A  16.00  1.00  S
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
59 0.50  0.25  I  >128.00  64.00  I 4.00  2.00  I 16.00  8.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
60 0.25  0.50  I  128.00  128.00  I >16.00  32.00  I 16.00  8.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
61 0.25  0.50  I  >128.00  64.00  I >16.00  4.00  S  16.00  8.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
62 1.00  0.50  I  >128.00  128.00  I 4.00  2.00  I 16.00  16.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
63 0.25  2.00  A  >128.00  8.00  S  16.00  8.00  I 16.00  2.00  S
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
64 0.25  0.13  I  128.00  64.00  I 2.00  2.00  I 16.00  8.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
65 0.25  1.00  A  >128.00  16.00  S  1.00  8.00  A  16.00  1.00  S
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
66 0.25  0.50  I  128.00  64.00  I 1.00  2.00  I 16.00  2.00  S
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
67 0.50  0.50  I  128.00  32.00  S  8.00  2.00  S  16.00  8.00  I
>64.00 0.50  >64.00  0.50  >64.00  0.50  >64.00  0.50
MICs,  minimal  inhibitory  concentrations  as  the  lowest  concentration  that  showed  100%  inhibition  of  fungal  growth  (g  mL−1);  AMB,
amphotericin B;  FCZ,  ﬂuconazole;  ITZ,  itraconazole;  CAS,  caspofungin;  FK506,  tacrolimus;  S,  synergism;  I,  indifference;  A,  antagonism.
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This compound exerts its effects by blocking the immune sys-
tem through inhibition of calcineurin.37 Moreover, this protein
can also affect essential functions of the fungal cell and it is
intrinsically involved in the growth and pathogenesis of three
major fungal species: Cryptococcus neoformans,  C. albicans, and
Aspergillus fumigatus.36,38 In this study, FK506 showed low anti-
fungal activity when tested alone against FS and FR T. asahii
isolates (MICs > 64.0 g mL−1).
However, against the FS group, the results of our study
(Table 2) demonstrate strong in vitro synergism of FK506
combined with drugs that were ineffective in inhibiting this
group of T. asahii clinical isolates (Table 1) such as caspofun-
gin (73.33%) and AMB  (96.67%). High percentage synergistic
interactions for caspofungin plus FK506 have been previously
reported against C. neoformans, Fusarium spp., and Aspergillus
spp.11,14,39
The potential enhanced antifungal activity of caspo-
fungin in combination with other antifungal agents and
anti-calcineurin drugs against clinical isolates of Fusarium spp.
was demonstrated by Shalit et al.11 The association of this
echinocandin with FK506 appeared synergistic against all the
isolates tested.11 The antifungal effect exhibited by immuno-
suppressants cyclosporin A and FK506 is probably related to
calmodulin activated protein phosphatase involved in fungal
stress response, virulence, and antifungal resistance.36 Stein-
bach et al.14 also demonstrated a synergistic interaction of
cyclosporin and FK506 with caspofungin against A. fumiga-
tus. In this study, the calcineurin inhibitors were capable of
causing a delay in ﬁlamentation of A. fumigatus,  which sug-
gested that inhibition of this pathway may potentiate the
action of conventional antifungal agents in combination ther-
apy against invasive aspergillosis.14
The pharmacokinetics of caspofungin is unaltered by
coadministration of tacrolimus, but caspofungin may reduce
tacrolimus concentrations by up to 20%.40 Therefore, monitor-
ing standard tacrolimus blood concentrations and appropriate
tacrolimus dose adjustments are recommended for patients
receiving both therapies.
On the other hand, the synergism observed with the
association of FK506 and AMB  can beneﬁt the antifungal ther-
apy regimen through the reductions in time to treatment
response, dose with associated toxicity, costs, and decreased
potential of microorganism-acquired resistance. Although
AMB  has been reported to have an insigniﬁcant effect on
tacrolimus metabolism,41 this polyene is well known to be
nephrotoxic. Therefore, monitoring of serum creatinine is
probably warranted for patients receiving both drugs.42
Studies have also shown that calcineurin inhibitors may
exert a synergistic interaction when combined with antifun-
gal azoles against Candida species.15,16 However, our results
demonstrated that combinations of FCZ or ITZ with FK506
produced interactions mainly indifferent emphasizing a lack
of effect against FS and FR T. asahii isolates (Tables 2 and 3).
The pharmacokinetics interactions between FK506 and azoles
are well known and show that azoles inhibit the metabolism
of FK506, requiring monitoring of the plasmatic concentration
of FK506.42
In conclusion, our ﬁndings demonstrated that the com-
bination of FK506 with AMB  or CAS leads to high rates
of synergism in vitro. These combinations against T. asahii
1 1 6;2  0(6):539–545
isolates that presented resistance to both AMB  and CAS
deserve attention as candidates for in vivo studies focusing
T. asahii experimental infections.
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